Persistence of fluoroquinolone-resistant, multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: Efforts to reduce intrafacility transmission

Infection Control and Hospital Epidemiology

Volumn 26, Issue 3, 2005, Pages 239-247

  Fry, Alicia M ^a,c   Udeagu, Chi Chi N ^e   Soriano Gabarro, Montse ^a,c   Fridkin, Scott ^b   Musinski, Diana ^f   LaClaire, Leslie ^a   Elliott, John ^a   Cook, Debra J P ^d   Kornblum, John ^d   Layton, Marcelle ^e   Whitney, Cynthia G ^a,c  

^a Respiratory Diseases Branch   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Public Health Laboratories

^e NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^f NE Counties Infect Contr P Netwk ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; HEALTH CARE FACILITY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TRACHEOSTOMY;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL VACCINES; CARRIER STATE; CROSS INFECTION; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FLUOROQUINOLONES; HEALTH FACILITIES; HUMANS; LONG-TERM CARE; LONGITUDINAL STUDIES; NASOPHARYNGEAL DISEASES; NEW YORK; PNEUMOCOCCAL INFECTIONS; PREVALENCE; RIFAMPIN; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 20144389541     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502533     Document Type: Article

References (22)

1. Strausbaugh LJ, Crossley KB, Nurse BA, et al. Antimicrobial resistance in long-term-care facilities. Infect Control Hosp Epidemiol 1996;17:129-140.
2. Gleich S, Morad Y, Echague R, et al. Streptococcus pneumoniae serotype 4 outbreak in a home for the aged: report and review of recent outbreaks. Infect Control Hosp Epidemiol 2000;21:711-717.
3. Whitney CG, Farley MN, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;346:1917-1924.
4. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-229.
5. Butler JC, Breiman RF, Campbell JF, et al. Polysaccharide pneumococcal vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-1831.
6. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325: 1453-1460.
7. Koivula I, Stén M, Leinenen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-290.
8. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318-1327.
9. Örtqvist Å, Hedlund J, Burman LÅ, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people. Lancet 1998;351:399-403.
10. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-2442.
11. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998;338:1861-1868.
12. Carter RJ, Sorenson G, Heffernan R, et al. Failure to control an outbreak of multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: emergence and ongoing transmission of a fluoroquinolone-resistant strain. Infect Control Hosp Epidemiol 2005;26:248-255.
13. O'Brien KL, Dagan R, Yagupsky P, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 2001;39:1021-1024.
14. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
15. Elliott JA, Farmer KD, Facklam RR. Sudden increase in isolation of Group B streptococci, serotype V, is not due to emergence of a new pulsed-field gel electrophoresis type. J Clin Microbiol 1998;36:2115-2116.
16. Garner JS. Guideline for isolation precautions in hospitals: the Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17:53-79.
17. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000;160:2633-2638.
18. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001;32:794-800.
19. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355:2106-2111.
20. Fedson DS. Pneumococcal conjugate vaccination for adults: why it's important for children. Pediatr Infect Dis J 2000;19:183-186.
21. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294:2170-2172.
22. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.